Clinical Trials Logo

Stable Coronary Artery Disease clinical trials

View clinical trials related to Stable Coronary Artery Disease.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06123728 Recruiting - Clinical trials for Stable Coronary Artery Disease

MCG is Clinically Applied to Evaluate Myocardial Ischemic Function in Patients With Stable Coronary Artery Disease

Start date: April 19, 2023
Phase:
Study type: Observational [Patient Registry]

The objective of this observational study is to evaluate the diagnostic effectiveness of magnetocardiography (MCG) in patients with stable coronary artery disease (SCAD) and compare it with coronary CTA (CCTA). Additionally, the study aims to determine the most suitable diagnostic index for MCG. The primary question it seeks to address is whether MCG or MCG combined with CCTA can be utilized to guide the clinical application of percutaneous coronary intervention (PCI) for coronary heart disease.

NCT ID: NCT03313752 Recruiting - Clinical trials for Type2 Diabetes Mellitus

Effects of SGLT2 Inhibition on Myocardial Insulin Sensitivity

DapaHeart
Start date: December 1, 2017
Phase: Phase 3
Study type: Interventional

A Phase III, single-centre, randomized, 2-arm, parallel-group, double blind, placebo-controlled study, consisting of a screening phase (Days -14 to -1), a 4-week double-blind, placebo-controlled treatment phase and a 4-week follow-up phase. Subjects: Type 2 diabetic patients and coronary artery diseases (CAD) not requiring revascularization or underwent percutaneous coronary intervention (PCI) but clinically stable at time of screening visit, with suboptimal glycaemic control (HbA1c 7.0-8.5%) on their current anti-hyperglycaemic regimen Subjects will be randomized in a 1:1 ratio to dapagliflozin or placebo. Subjects will undergo screening assessment in the 14-day period preceding administration of the first dose of study drug on Day 1. The primary Objective is to assess the effect of dapagliflozin on myocardial insulin sensitivity The Secondary Objective is to assess global heart function, and metabolic systemic effects of dapagliflozin, and glycemic control. The study aims to enroll patients with type 2 diabetes with suboptimal glycemic control, and with coronary artery diseases (CAD) not requiring revascularization or underwent percutaneous coronary intervention (PCI) but clinically stable, who have already undergone, under routine cardiological assessment, a positron emission tomography (PET) 13NH3 scan in order to assess the cardiovascular function. Thus, the study aims to assess whether the improvement in cardiac metabolism obtained with dapagliflozin is greater than that obtained with normal clinical practice (according to Standards of Care).

NCT ID: NCT03089450 Recruiting - Clinical trials for Ischemic Heart Disease

To Evaluate Safety and Efficacy of CGBIO Stent Compared to Biomatrix Flex Stent

Start date: March 22, 2017
Phase: N/A
Study type: Interventional

to evaluate safety and efficacy of CGBIO stent(DES) compared to Biomatrix flex stent(DES)